
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics is a clinical-stage biotechnology company with a strong focus on developing innovative drug candidates utilizing its POZ Platform delivery technology. Their main product candidate, SER-252, has shown promising results in treating Parkinson's disease and has the potential to become a blockbuster drug in the future. While facing common industry risks, the company has secured FDA approval for a faster regulatory pathway and continues to conduct trials for its drug candidates, positioning itself for potential success in the market.
Bears say
Serina Therapeutics is a clinical-stage biotechnology company with a negative outlook due to concerns about its technology platform, regulatory risks, and commercial potential. The company's POZ platform, which delivers drugs using polymer technology, may have potential limitations compared to other existing polymer technologies, and the recent clinical hold raises questions about the FDA's oversight. Furthermore, the market for advanced Parkinson's disease treatments is already crowded and the company may face challenges in obtaining pricing and reimbursement for its product candidate, SER-252. Additionally, while Serina has a deeper pipeline, its reliance on partnerships introduces uncertainty and decreases potential revenue.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares